Get the Stockscreener App
2.40
3.00%
0.07
After Hours:
2.31
-0.09
-3.75%
Palisade Bio Inc stock is traded at $2.40, with a volume of 3.53M.
It is up +3.00% in the last 24 hours and up +20.60% over the past month.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
See More
Previous Close:
$2.33
Open:
$2.35
24h Volume:
3.53M
Relative Volume:
0.87
Market Cap:
$402.29M
Revenue:
$250.00K
Net Income/Loss:
$-16.78M
P/E Ratio:
-1.6164
EPS:
-1.4848
Net Cash Flow:
$-10.85M
1W Performance:
+31.87%
1M Performance:
+20.60%
6M Performance:
+37.93%
1Y Performance:
+233.38%
1-Day Range:
$2.275
$2.45
1-Week Range:
$1.85
$2.45
52-Week Range:
$0.53
$2.64
Palisade Bio Inc Stock (PALI) Company Profile
Name
Palisade Bio Inc
Sector
Industry
Phone
(858) 704-4900
Address
7750 EL CAMINO REAL, SUITE 5200, CARLSBAD
Compare PALI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PALI
Palisade Bio Inc
|
2.40 | 402.29M | 250.00K | -16.78M | -10.85M | -1.4848 |
VRTX
Vertex Pharmaceuticals Inc
|
441.20 | 112.22B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
750.57 | 79.35B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
849.04 | 52.80B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.66 | 41.32B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
323.87 | 35.95B | 5.36B | 287.73M | 924.18M | 2.5229 |
Palisade Bio Inc Stock (PALI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-09-26 | Initiated | Wolfe Research | Outperform |
| Mar-26-26 | Initiated | H.C. Wainwright | Buy |
| Feb-25-26 | Initiated | Stifel | Buy |
| Jan-09-26 | Initiated | B. Riley Securities | Buy |
| Dec-29-25 | Initiated | Piper Sandler | Overweight |
Palisade Bio Inc Stock (PALI) Latest News
Palisade Bio (NASDAQ: PALI) asks shareholders to lift authorized shares to 450M - Stock Titan
Palisade Bio Develops Crohn’s Disease Treatment Following Positive Study - HarianBasis.co
Wolfe Highlights Differentiation Potential in Palisade Bio, Inc. (PALI) Clinical Profile - Insider Monkey
Palisade Bio to present ulcerative colitis data at DDW conference - Investing.com
Palisade Bio, Inc. Announces Poster Presentation at Digestive Disease Week® 2026 Featuring PALI-2108 Data on Ulcerative Colitis - Quiver Quantitative
Palisade Bio Announces Abstract Selected for Poster Presentation at Digestive Disease Week (DDW) 2026 - GlobeNewswire
5 Best Biotech Stocks Under $10 to Buy - Insider Monkey
Piper Sandler reiterates Overweight rating on Palisade Bio stock - Investing.com UK
Piper Sandler reiterates Overweight rating on Palisade Bio stock By Investing.com - Investing.com India
Here's Why Palisade Bio (PALI) Could be Great Choice for a Bottom Fisher - MSN
Palisade Bio, Inc. (NASDAQ:PALI) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Should I invest in Palisade Bio Inc before earnings2026 Performance Recap & Expert Curated Trade Setup Alerts - baoquankhu1.vn
Wolfe Research Upgrades Palisade Bio (NASDAQ:PALI) to Strong-Buy - MarketBeat
Wolfe Research Begins Coverage on Palisade Bio (NASDAQ:PALI) - MarketBeat
Palisade Bio to Present at the Needham & Co. 25th Annual Healthcare Conference - The Manila Times
Palisade Bio CEO, CMO to give virtual Needham presentation April 16 - Stock Titan
Palisade Bio (PALI) reports positive phase 1b data for PALI-2108 in UC patients - MSN
Earnings Miss: Can Palisade Bio Inc expand its profit margins2026 Opening Moves & Weekly High Return Opportunities - baoquankhu1.vn
Analysts Conflicted on These Healthcare Names: Neumora Therapeutics, Inc. (NMRA), Palisade Bio (PALI) and AnaptysBio (ANAB) - The Globe and Mail
PALI Should I Buy - Intellectia AI
Palisade Bio partners with Iterative Health to advance PALI-2108 - TipRanks
Palisade Bio enters agreement with Iterative Health and completes $3 million stock sale - Investing.com Australia
Palisade Bio raises $3.0M from Iterative Health affiliate to support PALI-2108 Phase 2 enrollment - TradingView — Track All Markets
Palisade Bio (NASDAQ: PALI) sells 1.54M shares to Iterative Health affiliate - Stock Titan
Palisade Bio, Inc. (PALI) stock price, news, quote and history - Yahoo Finance UK
Clear Street Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Edwards Lifesciences (EW) and Palisade Bio (PALI) - The Globe and Mail
Clear Street reiterates Palisade Bio stock rating on trial data By Investing.com - Investing.com South Africa
Update: Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease - moomoo.com
Clear Street reiterates Palisade Bio stock rating on trial data - Investing.com
Palisade Bio Shares Fall After Phase 1b Data on PALI-2108 in Fibrostenotic Crohn's Disease - marketscreener.com
Palisade Bio Shares Phase 1b PALI-2108 Data Showing Safety, PK and Early Crohn’s Efficacy Signals - MarketBeat
Support Test: Can Palisade Bio Inc beat the S P 500Market Growth Summary & Weekly Momentum Picks - baoquankhu1.vn
Palisade Bio posts trial data for lead asset (PALI:NASDAQ) - Seeking Alpha
Crafting a New Financial Era: Palisade Bio Inc.’s Strategic Moves - StocksToTrade
Palisade Bio stock maintains buy rating at Stifel on trial data - Investing.com Australia
Palisade Bio stock maintains buy rating at Stifel on trial data By Investing.com - Investing.com South Africa
H.C. Wainwright Maintains Palisade Bio(PALI.US) With Buy Rating, Maintains Target Price $7 - moomoo.com
Palisade Bio reports Phase 1b trial results for Crohn’s drug By Investing.com - Investing.com South Africa
Palisade Bio reports Phase 1b trial results for Crohn’s drug - Investing.com
Palisade Bio Reports Positive Topline Data from Phase 1b Clinical Study of PALI-2108 in Fibrostenotic Crohn’s Disease - GlobeNewswire
HC Wainwright Forecasts Palisade Bio Q1 Earnings - MarketBeat
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
HC Wainwright Begins Coverage on Palisade Bio (NASDAQ:PALI) - marketbeat.com
Big Picture: Can Palisade Bio Inc expand its profit marginsMarket Performance Summary & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Palisade Bio Inc Stock (PALI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Palisade Bio Inc Stock (PALI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Finley John David | CEO, CFO |
Feb 12 '26 |
Sale |
1.75 |
3,896 |
6,818 |
27,353 |
| Williams Donald Allen | Director |
Jan 16 '26 |
Buy |
1.67 |
5,000 |
8,356 |
10,728 |
| Williams Donald Allen | Director |
Jan 09 '26 |
Buy |
1.88 |
5,000 |
9,400 |
5,728 |
2.19%
0.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):